Another month passed without a readout of Elicio’s AMPLIFY-7P. The Phase 2 study tests therapeutic KRAS vaccine ELI-002 7P in patients with resected pancreatic cancer.

The adjuvant trial is event-driven, meaning it reads out once a certain number of relapses (and deaths) have accumulated. Assuming uniform enrollment from January to December 2024, the median patient was dosed around July 2024, now around 21 months ago.

Compared to historical disease-free survival in this population, every passing month without a readout makes the null less likely and the case for vaccine efficacy stronger.